1
|
Wang T, Xing J, Ying Y, Tang H, Li J, Wei Y, Zhang H. Notch1 signaling mediated dysfunction of bone marrow mesenchymal stem cells derived from cyanotic congenital heart disease. Biochem Biophys Res Commun 2020; 527:847-853. [PMID: 32430170 DOI: 10.1016/j.bbrc.2020.04.129] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 04/24/2020] [Indexed: 11/26/2022]
Abstract
Bone marrow mesenchymal stem cells (BMSCs) derived from cyanotic congenital heart disease (CCHD) exhibit deficient multi-lineage differentiation potential due to the abnormal accumulation of D-galactose. However, the underlying mechanisms have not yet been explored. Here, the multi-lineage differentiation potential of the BMSCs from CCHD and non-CCHD (NCHD) patients were assessed. BMSCs from CCHD patients exhibited inferior multi-lineage differentiation potential with reduced Notch1 protein and mRNA level. Bisulfite sequencing PCR results showed the methylation level of Notch1 promoter was raised, which inhibited the binding of NF-Ya. Exposure BMSCs from NCHD patients with D-galactose under hypoxia (4% O2) decreased the expression of Notch1. And activating Notch1 partially restored the deficient BMSCs of CCHD patients. In conclusion, the impaired multi-lineage differentiation potential of BMSCs from CCHD patients is owing to the decreased Notch1 level with a remarkable hypermethylation in its promoter region. Activated Notch1 signaling pathway could partially restore the deficient BMSCs in the CCHD patients, which may provide a new method on cell therapy in patients with CCHD.
Collapse
Affiliation(s)
- Tingting Wang
- State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
| | - Junyue Xing
- State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China; Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital, Key Laboratory for Cardiac Regenerative Medicine, National Health Commission & Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, 450003, China; Heart Center and Shanghai Institution of Pediatric Congenital Heart Diseases, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China
| | - Yongquan Ying
- Department of Thoracic and Cardiovascular Surgery, Taizhou Hospital, Zhejiang, 317000, China
| | - Hao Tang
- Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital, Key Laboratory for Cardiac Regenerative Medicine, National Health Commission & Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, 450003, China
| | - Jun Li
- State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
| | - Yingjie Wei
- State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
| | - Hao Zhang
- State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China; Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital, Key Laboratory for Cardiac Regenerative Medicine, National Health Commission & Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, 450003, China; Heart Center and Shanghai Institution of Pediatric Congenital Heart Diseases, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
| |
Collapse
|
2
|
Xu Z, Sun Y, Guo Y, Qin G, Mu S, Fan R, Wang B, Gao W, Wu H, Wang G, Zhang Z. NF-YA promotes invasion and angiogenesis by upregulating EZH2-STAT3 signaling in human melanoma cells. Oncol Rep 2016; 35:3630-8. [PMID: 27109360 DOI: 10.3892/or.2016.4761] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Accepted: 02/22/2016] [Indexed: 11/06/2022] Open
Abstract
The process of angiogenesis is essential for tumor development and metastasis. Vascular endothelial growth factor (VEGF), which is overexpressed in most human cancers, has been demonstrated to be a major modulator of angiogenesis. Thus, inhibition of VEGF signaling has the potential for tumor anti-angiogenic therapy. Signal transducer and activator of transcription-3 (STAT3) is a key regulator for angiogenesis by directly binding to the VEGF promoter to upregulate its transcription. Several factors can enhance STAT3 activity to affect angiogenesis. Here, we found that overexpression of nuclear transcription factor-Y alpha (NF-YA) gene could promote cell invasion and angiogenesis accompanying the increase of STAT3 signaling in human melanoma cells. Moreover, the expression and secretion of VEGF was also found to be upregulated by the overexpression of NF-YA gene in melanoma cells. The STAT3 inhibitor was able to attenuate the upregulation of VEGF induced by NF-YA overexpression. Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the Polycomb repressive complex 2, enhances STAT3 activity by mediating its lysine methylation. We also showed that NF-YA upregulated the expression of EZH2 and NF-YA‑induced angiogenesis could be inhibited by EZH2 knockdown. Taken together, these findings indicate that overexpression of NF-YA contributes to tumor angiogenesis through EZH2-STAT3 signaling in human melanoma cells, highlighting NF-YA as a potential therapeutic target in human melanoma.
Collapse
Affiliation(s)
- Zihan Xu
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| | - Yaowen Sun
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| | - Yadong Guo
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| | - Gaoping Qin
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| | - Shengzhi Mu
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| | - Ronghui Fan
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| | - Benfeng Wang
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| | - Wenjie Gao
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| | - Hangli Wu
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| | - Guodong Wang
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| | - Zhenxin Zhang
- Department of Burns and Plastic Surgery, Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
| |
Collapse
|